# Phase I/II Study of hLL1 in Multiple Myeloma

> **NCT00421525** · PHASE1,PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 25 (actual)

## Conditions studied

- Multiple Myeloma
- Myeloma, Plasma-Cell
- PLASMACYTOMA

## Interventions

- **BIOLOGICAL:** milatuzumab

## Key facts

- **NCT ID:** NCT00421525
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421525, "Phase I/II Study of hLL1 in Multiple Myeloma". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00421525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*